Isabel Kalofonos

Isabel Kalofonos serves as Chief Commercial Officer at CG Oncology and brings more than 20 years of experience driving successful launches and commercial execution in the biotechnology and pharmaceutical industries to her role. Most recently, she served as Chief Commercial Officer of Crinetics Pharmaceuticals (acquired by Vertex Pharmaceuticals), where she played a key role in the company’s transition to the commercial stage, helping to drive the successful launch of PALSONIFY^™ (paltusotine) and advance commercial planning across the pipeline.

Prior to Crinetics, Ms. Kalofonos served as Chief Commercial Officer at ImmunoGen (acquired by AbbVie), where she led the successful launch of ELAHERE^® (mirvetuximab soravtansine) in ovarian cancer. Earlier in her career, Ms. Kalofonos served as Senior Vice President and Global Head of the Prescription Business Unit at Galderma, where she oversaw the build-out of the business unit and pre-launch preparations for NEMLUVIO^® (nemolizumab). She also served as Vice President and Head of the Hereditary Angioedema Franchise at Takeda Pharmaceuticals (formerly Shire), leading a multi-billion-dollar business and the successful global launch of TAKHZYRO^® (lanadelumab‑flyo). Throughout her career, she has built and led high-performing global commercial organizations across oncology, immunology, rare diseases, and neurology.

Ms. Kalofonos holds an M.B.A. in Entrepreneurship and Marketing from Babson College and a bachelor's degree in Industrial Engineering from Pontificia Universidad Javeriana.